ES2687971T3 - Diagnóstico de sufrimiento fetal - Google Patents
Diagnóstico de sufrimiento fetal Download PDFInfo
- Publication number
- ES2687971T3 ES2687971T3 ES14772109.6T ES14772109T ES2687971T3 ES 2687971 T3 ES2687971 T3 ES 2687971T3 ES 14772109 T ES14772109 T ES 14772109T ES 2687971 T3 ES2687971 T3 ES 2687971T3
- Authority
- ES
- Spain
- Prior art keywords
- uric acid
- sample
- samples
- fetal distress
- fetal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032943 Fetal Distress Diseases 0.000 title claims abstract description 30
- 206010016855 Foetal distress syndrome Diseases 0.000 title claims abstract description 30
- 238000003745 diagnosis Methods 0.000 title claims abstract description 21
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 83
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229940116269 uric acid Drugs 0.000 claims abstract description 52
- 201000011461 pre-eclampsia Diseases 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000012544 monitoring process Methods 0.000 claims abstract description 17
- 230000035935 pregnancy Effects 0.000 claims description 33
- 210000003296 saliva Anatomy 0.000 claims description 27
- 230000001605 fetal effect Effects 0.000 claims description 10
- 208000030941 fetal growth restriction Diseases 0.000 claims description 10
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 8
- 230000008774 maternal effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 206010070538 Gestational hypertension Diseases 0.000 claims description 6
- 208000004104 gestational diabetes Diseases 0.000 claims description 6
- 210000002826 placenta Anatomy 0.000 claims description 6
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 5
- 230000002028 premature Effects 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 208000002296 eclampsia Diseases 0.000 claims description 4
- 230000035487 diastolic blood pressure Effects 0.000 claims description 2
- 230000035488 systolic blood pressure Effects 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims 2
- 206010049119 Emotional distress Diseases 0.000 abstract 1
- 230000009429 distress Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000002159 abnormal effect Effects 0.000 description 12
- 210000003754 fetus Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 201000005608 severe pre-eclampsia Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000036818 High risk pregnancy Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316668.1A GB201316668D0 (en) | 2013-09-19 | 2013-09-19 | Diagnosis of foetal distress |
| GB201316668 | 2013-09-19 | ||
| PCT/EP2014/070053 WO2015040190A1 (en) | 2013-09-19 | 2014-09-19 | Diagnosis of foetal distress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2687971T3 true ES2687971T3 (es) | 2018-10-30 |
Family
ID=49553104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14772109.6T Active ES2687971T3 (es) | 2013-09-19 | 2014-09-19 | Diagnóstico de sufrimiento fetal |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160231306A1 (enExample) |
| EP (1) | EP3047269B1 (enExample) |
| JP (1) | JP6456394B2 (enExample) |
| CA (1) | CA2922894C (enExample) |
| DK (1) | DK3047269T3 (enExample) |
| ES (1) | ES2687971T3 (enExample) |
| GB (1) | GB201316668D0 (enExample) |
| WO (1) | WO2015040190A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3442415B1 (en) | 2016-04-14 | 2025-05-28 | Morgan Innovation & Technology Ltd | Methods for measuring the levels of analytes in body fluids |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313828D0 (en) * | 2003-06-16 | 2003-07-23 | Owen Smith Brian D O | Salivary urate for diagnosis of pre-eclampsia |
-
2013
- 2013-09-19 GB GBGB1316668.1A patent/GB201316668D0/en not_active Ceased
-
2014
- 2014-09-19 CA CA2922894A patent/CA2922894C/en active Active
- 2014-09-19 EP EP14772109.6A patent/EP3047269B1/en active Active
- 2014-09-19 WO PCT/EP2014/070053 patent/WO2015040190A1/en not_active Ceased
- 2014-09-19 US US15/023,002 patent/US20160231306A1/en not_active Abandoned
- 2014-09-19 DK DK14772109.6T patent/DK3047269T3/en active
- 2014-09-19 JP JP2016543421A patent/JP6456394B2/ja active Active
- 2014-09-19 ES ES14772109.6T patent/ES2687971T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2922894A1 (en) | 2015-03-26 |
| EP3047269A1 (en) | 2016-07-27 |
| WO2015040190A1 (en) | 2015-03-26 |
| JP6456394B2 (ja) | 2019-01-23 |
| CA2922894C (en) | 2022-05-03 |
| DK3047269T3 (en) | 2018-09-17 |
| EP3047269B1 (en) | 2018-08-01 |
| US20160231306A1 (en) | 2016-08-11 |
| JP2016531305A (ja) | 2016-10-06 |
| GB201316668D0 (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114127861A (zh) | 使用包括收缩压、血液学参数及其组合的生命体征检测败血症的方法 | |
| Josten et al. | Umbilical cord blood pH and Apgar scores as an index of neonatal health | |
| Black | Obstetrics in the time of Ebola: Challenges and dilemmas in providing life-saving care during a deadly epidemic | |
| US20170052193A1 (en) | Fertility and pregnancy monitoring device and method | |
| Christiaens et al. | Validity of intrapartum diagnosis of fetal thrombocytopenia | |
| ES2687971T3 (es) | Diagnóstico de sufrimiento fetal | |
| RU2342662C1 (ru) | Способ прогнозирования синдрома задержки внутриутробного развития плода у женщин во втором триместре беременности при гриппе а(h3n2) в первом триместре гестации | |
| Shamoon et al. | Prevalence and etiological classification of thrombocytopenia among a group of pregnant women in Erbil City, Iraq | |
| Sabato et al. | Racial Disparities in Postpartum Hemorrhage in a Community Hospital: A Retrospective Cohort Analysis [24C] | |
| Haverkamp et al. | An assessment of electronic fetal monitoring | |
| Cohen et al. | Management of labor: are the new guidelines justified? | |
| Rodier et al. | Does treatment of premature labor with terbutaline increase the risk of autism spectrum disorders? | |
| Nesrallah et al. | The effect of timing of removal of wound dressing on surgical site infection rate after cesarean delivery [23N] | |
| RU2836096C1 (ru) | Способ прогнозирования внутрижелудочковых кровоизлияний у недоношенных новорожденных гестационного возраста 28-36,6 недель в раннем неонатальном периоде | |
| RU2816804C1 (ru) | Способ прогноза самопроизвольного прерывания беременности после перенесённой новой коронавирусной инфекции (НКВИ) лёгкой и среднетяжёлой формы | |
| RU2499547C1 (ru) | Способ дифференциальной диагностики гипертензивных состояний при беременности | |
| RU2755965C1 (ru) | Способ прогнозирования риска тяжелой церебральной ишемии у новорожденных с низкой и очень низкой массой тела при преждевременных родах, инициированных преждевременным разрывом плодных оболочек | |
| Bonacquisto | Antenatal screening: the first and second trimester | |
| Montobbio | Danno renale nel neonato prematuro: fattori di rischio, conseguenze a lungo termine e approccio multidisciplinare per la diagnosi precoce. | |
| RU2521359C2 (ru) | Способ определения степени тяжести гестоза у беременных | |
| Mohamed et al. | How safely can post-term pregnancies with uncertain gestational age be followed up using amniotic fluid index measurements? | |
| REDDY | EVALUATION OF CARDIOTOCOGRAPHY MONITORING IN INTRAPARTUM FOETAL SURVEILLANCE AND ITS CORRELATION WITH APGAR SCORE AND CORD BLOOD pH | |
| Muzaffar et al. | Validating the Diagnostic Accuracy of Dipstick Urine Analysis in Single Voided Urine by using 24 Hours Collection as Gold Standard for Diagnosis of Proteinuria in Patients with Pregnancy Induced Hypertension | |
| RU2472438C1 (ru) | Способ прогнозирования перинатальной патологии у новорожденных | |
| Sinno et al. | Point-of-Care vs Laboratory Based Urine Protein-Creatinine Ratio as an Indicator of Proteinuria in Pregnancy [9N] |